Business Context and Reporting Period
Company: NERVGEN PHARMA CORP.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2026
Date of Filing: January 8, 2026
Headquarters: Vancouver, British Columbia, Canada
This filing serves as a notification of a Material Change Report (Exhibit 99.1) dated January 8, 2026, which is incorporated by reference into the registrant's Registration Statement on Form F-10 (File No. 333-292197).
Financial Metrics
The provided filing text does not contain specific financial data. No values are reported for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing indicates the occurrence of a material change as of January 8, 2026. However, the specific nature of this change is not detailed in the cover page text and is contained within the referenced Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, specific risks, contingencies, or details regarding unusual items. These details are expected to be found in the incorporated Material Change Report.
Key Facts for Investor Verification
- Verify the specific content of the Material Change Report (Exhibit 99.1) to understand the nature of the event reported on January 8, 2026.
- Review the Registration Statement on Form F-10 (File No. 333-292197) for context regarding the incorporation of this report.
- Confirm that no financial statements or quantitative metrics are included in this specific Form 6-K cover page.